Oak Street Health, Inc. to Post FY2021 Earnings of ($1.89) Per Share, Piper Sandler Forecasts (NYSE:OSH)

Oak Street Health, Inc. (NYSE:OSH) – Equities research analysts at Piper Sandler cut their FY2021 EPS estimates for Oak Street Health in a research report issued to clients and investors on Tuesday, January 11th. Piper Sandler analyst S. Wieland now forecasts that the company will post earnings of ($1.89) per share for the year, down from their prior estimate of ($1.88). Piper Sandler also issued estimates for Oak Street Health’s Q4 2021 earnings at ($0.67) EPS, Q2 2022 earnings at ($0.52) EPS, Q3 2022 earnings at ($0.68) EPS, FY2022 earnings at ($2.56) EPS, Q1 2023 earnings at ($0.65) EPS, Q2 2023 earnings at ($0.69) EPS, Q3 2023 earnings at ($0.74) EPS, Q4 2023 earnings at ($0.92) EPS, FY2023 earnings at ($3.00) EPS and FY2024 earnings at ($3.05) EPS.

Oak Street Health (NYSE:OSH) last announced its quarterly earnings data on Monday, November 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.02). Oak Street Health had a negative net margin of 27.80% and a negative return on equity of 133.13%. The firm had revenue of $388.70 million during the quarter, compared to analysts’ expectations of $357.53 million. During the same period in the prior year, the company posted ($0.15) EPS. The company’s revenue for the quarter was up 78.4% compared to the same quarter last year.

A number of other research firms have also recently commented on OSH. Cowen cut Oak Street Health from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $48.00 to $25.00 in a report on Monday, January 10th. Truist decreased their price target on Oak Street Health from $72.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, October 13th. Truist Securities cut their price objective on Oak Street Health from $72.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, October 13th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $33.00 target price (down previously from $44.00) on shares of Oak Street Health in a research report on Friday, December 17th. Finally, Zacks Investment Research upgraded shares of Oak Street Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 19th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Oak Street Health currently has an average rating of “Buy” and an average price target of $57.82.

Oak Street Health stock opened at $22.00 on Thursday. The firm has a 50 day simple moving average of $32.75 and a 200-day simple moving average of $44.62. The stock has a market cap of $5.30 billion, a price-to-earnings ratio of -13.58 and a beta of 1.14. The company has a debt-to-equity ratio of 5.88, a current ratio of 2.78 and a quick ratio of 2.78. Oak Street Health has a 1-year low of $21.56 and a 1-year high of $66.31.

Large investors have recently made changes to their positions in the business. Capital International Investors boosted its position in shares of Oak Street Health by 16.8% during the 2nd quarter. Capital International Investors now owns 8,875,349 shares of the company’s stock worth $519,829,000 after acquiring an additional 1,277,619 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Oak Street Health by 48.2% during the 2nd quarter. Vanguard Group Inc. now owns 8,682,834 shares of the company’s stock worth $508,554,000 after acquiring an additional 2,822,067 shares in the last quarter. BlackRock Inc. lifted its stake in Oak Street Health by 34.0% during the third quarter. BlackRock Inc. now owns 7,308,774 shares of the company’s stock worth $310,841,000 after purchasing an additional 1,854,780 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Oak Street Health by 3.9% in the third quarter. Wellington Management Group LLP now owns 6,710,394 shares of the company’s stock valued at $285,393,000 after purchasing an additional 253,224 shares in the last quarter. Finally, Capital Research Global Investors purchased a new position in Oak Street Health in the third quarter valued at approximately $139,805,000. 85.67% of the stock is currently owned by institutional investors.

In other Oak Street Health news, CEO Michael T. Pykosz sold 50,000 shares of the company’s stock in a transaction dated Tuesday, October 19th. The stock was sold at an average price of $41.82, for a total transaction of $2,091,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael T. Pykosz sold 25,000 shares of Oak Street Health stock in a transaction dated Tuesday, January 4th. The shares were sold at an average price of $33.19, for a total value of $829,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 401,541 shares of company stock worth $16,002,409. 10.10% of the stock is owned by insiders.

Oak Street Health Company Profile

Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas.

Featured Story: Liquidity

Earnings History and Estimates for Oak Street Health (NYSE:OSH)

Receive News & Ratings for Oak Street Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oak Street Health and related companies with MarketBeat.com's FREE daily email newsletter.